Avid Bioservices, Inc. revised revenue guidance for the full fiscal year 2024. The company is adjusting revenue guidance for full fiscal year 2024 to $137 million to $147 million, previously $145 million and $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.96 USD | -7.66% | -12.43% | +22.46% |
04-30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
04-29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.46% | 506M | |
-2.91% | 89.01B | |
-4.34% | 37.79B | |
-17.08% | 31.22B | |
+60.01% | 26.1B | |
-22.15% | 14.25B | |
-9.36% | 12.8B | |
-11.39% | 11.65B | |
-46.06% | 10.88B | |
+3.67% | 8.7B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024